U.S. states pleaded with the Trump administration to coordinate a national response to the coronavirus outbreak, saying patchwork measures enacted by state and local authorities were insufficient to confront the coast-to-coast emergency.

The United States is preparing for thousands of new coronavirus cases and will ask Americans returning from abroad to go into “self-quarantine” for 14 days as part of the effort to contain the outbreak, Vice President Mike Pence said.

Seemingly in response to global uncertainty over the coronavirus outbreak, the stock markets have plunged, numerous conferences are being canceled and biopharma companies are taking action.

U.S. President Donald Trump will meet with Treasury Secretary Steven Mnuchin and other economic officials to weigh possible actions to stem the fallout from a widening coronavirus outbreak, an administration official told Reuters.

An outbreak of coronavirus in New York could cause more sharp selling of stocks, but markets would likely continue to function even if the floor of the New York Stock Exchange had to close.

Novacyt plans to launch a certified test for the coronavirus, sending the biotechnology company’s London-listed shares to a record high.

Vir Biotechnology priced the company’s initial public offering (IPO) at $20 a share, at the bottom end of expectations, the latest underwhelming investment performance for a stock held by SoftBank Group Corp.’s Vision Fund.

Copenhagen, Denmark-based Genmab A/S raised $506 million with an initial public offering (IPO), with the company trading on the Nasdaq under the ticker symbol GMAB.

FDA Commissioner Scott Gottlieb plans to step down in April 2019, a sudden resignation that calls into question how the regulatory agency will handle issues such as surging e-cigarette use among teens and efforts to increase competition in prescription drugs.

Fueled by a desire for innovation and new medical breakthroughs, the biotech industry continues to enjoy substantial growth due to increased investment in R&D.